Trial
NCT04120883
Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Michigan
Collaborators
Cures Within Reach
Condition
Retinitis Pigmentosa
Intervention
Hydroxychloroquine lower dose
Why stopped
Unable to recruit additional participants after multiple extensions to planned enrollment period.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-26